Year |
Citation |
Score |
2023 |
Kalita M, Park JH, Kuo RC, Hayee S, Marsango S, Straniero V, Alam IS, Rivera-Rodriguez A, Pandrala M, Carlson ML, Reyes ST, Jackson IM, Suigo L, Luo A, Nagy SC, et al. PET Imaging of Innate Immune Activation Using C Radiotracers Targeting GPR84. Jacs Au. 3: 3297-3310. PMID 38155640 DOI: 10.1021/jacsau.3c00435 |
0.821 |
|
2023 |
Carlson ML, Jackson IM, Azevedo EC, Reyes ST, Alam IS, Kellow R, Castillo JB, Nagy SC, Sharma R, Brewer M, Cleland J, Shen B, James ML. Development and Initial Assessment of [F]OP-801: a Novel Hydroxyl Dendrimer PET Tracer for Preclinical Imaging of Innate Immune Activation in the Whole Body and Brain. Molecular Imaging and Biology. PMID 37735280 DOI: 10.1007/s11307-023-01850-5 |
0.812 |
|
2023 |
Jackson IM, Carlson ML, Beinat C, Malik N, Kalita M, Reyes S, Azevedo EC, Nagy SC, Alam IS, Sharma R, La Rosa SA, Moradi F, Cleland J, Shen B, James ML. Clinical Radiosynthesis and Translation of [F]OP-801: A Novel Radiotracer for Imaging Reactive Microglia and Macrophages. Acs Chemical Neuroscience. PMID 37310119 DOI: 10.1021/acschemneuro.3c00028 |
0.79 |
|
2022 |
Jackson IM, Buccino PJ, Azevedo EC, Carlson ML, Luo ASZ, Deal EM, Kalita M, Reyes ST, Shao X, Beinat C, Nagy SC, Chaney AM, Anders DA, Scott PJH, Smith M, et al. Radiosynthesis and initial preclinical evaluation of [C]AZD1283 as a potential P2Y12R PET radiotracer. Nuclear Medicine and Biology. PMID 35680502 DOI: 10.1016/j.nucmedbio.2022.05.001 |
0.748 |
|
2022 |
Jackson IM, Webb EW, Scott PJH, James ML. Approaches for Addressing Challenges in CNS Radiopharmaceutical Design. Acs Chemical Neuroscience. PMID 35606334 DOI: 10.1021/acschemneuro.2c00269 |
0.649 |
|
2022 |
Lucot KL, Stevens MY, Bonham TA, Azevedo EC, Chaney AM, Webber ED, Jain P, Klockow JL, Jackson IM, Carlson ML, Graves EE, Montine TJ, James ML. TRACKING INNATE IMMUNE ACTIVATION IN A MOUSE MODEL OF PARKINSON'S DISEASE USING TREM1 AND TSPO PET TRACERS. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 35177426 DOI: 10.2967/jnumed.121.263039 |
0.664 |
|
2020 |
Jackson IM, Lee SJ, Sowa AR, Rodnick ME, Bruton L, Clark M, Preshlock S, Rothley J, Rogers VE, Botti LE, Henderson BD, Hockley BG, Torres J, Raffel DM, Brooks AF, et al. Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC). Ejnmmi Radiopharmacy and Chemistry. 5: 24. PMID 33175263 DOI: 10.1186/s41181-020-00110-z |
0.347 |
|
2020 |
Stevens MY, Cropper HC, Lucot KL, Chaney AM, Lechtenberg KJ, Jackson IM, Buckwalter MS, James ML. Development of a CD19 PET tracer for detecting B cells in a mouse model of multiple sclerosis. Journal of Neuroinflammation. 17: 275. PMID 32948198 DOI: 10.1186/s12974-020-01880-8 |
0.678 |
|
2020 |
Jain P, Chaney A, Carlson ML, Jackson IM, Rao A, James ML. Neuroinflammation PET imaging: Current opinion and future directions. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32620705 DOI: 10.2967/jnumed.119.229443 |
0.759 |
|
2018 |
Sowa AR, Jackson IM, Desmond TJ, Alicea J, Mufarreh AJ, Pham JM, Stauff J, Winton WP, Fawaz MV, Henderson BD, Hockley BG, Rogers VE, Koeppe RA, Scott PJH. Futureproofing [F]Fludeoxyglucose manufacture at an Academic Medical Center. Ejnmmi Radiopharmacy and Chemistry. 3: 12. PMID 30363401 DOI: 10.1186/S41181-018-0048-X |
0.333 |
|
2016 |
Brooks AF, Drake LR, Stewart MN, Cary BP, Jackson IM, Mallette D, Mossine AV, Scott PJ. Fluorine-18 patents (2009-2015). Part 1: novel radiotracers. Pharmaceutical Patent Analyst. 5: 17-47. PMID 26670619 DOI: 10.4155/Ppa.15.36 |
0.454 |
|
Show low-probability matches. |